Clinical Trials Logo

Clinical Trial Summary

The multicenter, prospective, observational, non-interventional study conducted in German Stroke Units is investigating patients with intracranial hemorrhage (ICH) under effective anticoagulation with rivaroxaban or apixaban. The aim of the study is to analyze under routine conditions wether the volume increase of ICH under treatment with rivaroxaban and apixaban can be reduced with the antidote andexanet alfa. Thus, data of patients under effective treatment with rivaroxaban or apixaban and treated with andexanet alfa at baseline will be assessed at the time of onset of ICH, during the hospital stay and during a follow-up by telephone at 30 and 90 days after hospital discharge. The main objective is defined as the change in size or volume of the hematoma by computed tomography (CT) or magnetic resonance imaging (MRI) in patients with ICH under effective treatment with rivaroxaban and apixaban, who are treated with andexanet alfa. Further objectives comprise evaluations concerning the functional status according to modified Rankin Scale (mRS), changes in the National Institutes of Health Stroke Scale (NIHSS), and occurrences of ICH or new intraventricular bleeding as well as mortality rates.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05127941
Study type Observational
Source University Hospital, Essen
Contact
Status Active, not recruiting
Phase
Start date December 8, 2021
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03969732 - Multimodal Biomarkers for Diagnosis and Prognosis in CAA Phase 3
Recruiting NCT05968053 - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Recruiting NCT02962349 - TRansfusion Strategies in Acute Brain INjured Patients N/A
Recruiting NCT03950076 - EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) Phase 4
Completed NCT03542656 - Application of Amyloid PET in Cerebral Amyloid Angiopathy Phase 3
Active, not recruiting NCT05626504 - Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured Aneurysms
Recruiting NCT03495206 - Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet Phase 1
Not yet recruiting NCT04229758 - Restarting Anticoagulation After Traumatic Intracranial Hemorrhage Phase 3
Recruiting NCT02135783 - Decompressive Craniectomy Combined With Hematoma Removal to Treat ICH N/A
Enrolling by invitation NCT02050971 - Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates Phase 1
Completed NCT01193270 - Vitamin E for Extremely Preterm Infants Phase 1
Completed NCT02881957 - Hypovitaminosis D in Neurocritical Patients Phase 2/Phase 3
Completed NCT03364634 - Intracranial Pressure After Decompressive Craniectomy N/A
Completed NCT00226096 - Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage N/A
Recruiting NCT06081283 - Antiseizure Medication in Seizure Networks at Early Acute Brain Injury Phase 4
Recruiting NCT04459806 - Intracranial PrEssure Time dOse (ImPETO)
Recruiting NCT05874050 - Arterial Pressure and Surgical Hemostasis in Elective Neurosurgery.
Not yet recruiting NCT05138341 - Minimal Invasive Surgical Intracerebral Hemorrhage Removal N/A
Terminated NCT03660618 - LSFG-SKIN, Laser Speckle Flowgraphy N/A
Recruiting NCT06370520 - Screening Emotions in Adolescents at the Hospital for mTBI